Oculis S.A. is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.
Products, services, technology
OCS-01 being developed in DME and Post-ocular surgery inflammation;
OCS-02 being developed for Dry Eye Disease and Uveitis;
Pre-clinical candidates for retinal disorders and for ocular inflammation
-
+41 21 711 39 70
-
Louie-Anne Gauthier
